BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Liaw YF. Perspectives on current controversial issues in the management of chronic HBV infection. J Gastroenterol 2022. [PMID: 36053366 DOI: 10.1007/s00535-022-01918-z] [Reference Citation Analysis]
2 Broennimann K, Ricardo-lax I, Adler J, Shaul Y. Evidence for a Hepatitis B Virus Short RNA Fragment Directly Targeting the Cellular RRM2 Gene. Cells 2022;11:2248. [DOI: 10.3390/cells11142248] [Reference Citation Analysis]
3 Broquetas T, Carrión JA. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. HMER 2022;Volume 14:87-100. [DOI: 10.2147/hmer.s291976] [Reference Citation Analysis]
4 Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
5 Liaw YF, Chien RN. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation". Kaohsiung J Med Sci 2022. [PMID: 35262284 DOI: 10.1002/kjm2.12518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chien RN, Liaw YF. Current Trend in Antiviral Therapy for Chronic Hepatitis B. Viruses 2022;14:434. [PMID: 35216027 DOI: 10.3390/v14020434] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
7 Chang ML, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci 2022;23:1552. [PMID: 35163476 DOI: 10.3390/ijms23031552] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
8 Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
9 Riveiro-Barciela M, Pericàs JM, Buti M. How to interpret viral markers in the management of chronic hepatitis B infection. Clin Microbiol Infect 2021:S1198-743X(21)00622-4. [PMID: 34768018 DOI: 10.1016/j.cmi.2021.10.020] [Reference Citation Analysis]
10 Jindal A. Severity of Hepatitis B Relapse After Cessation of Nucleos(t)ide Analog: Need a Closer Look! Clin Gastroenterol Hepatol 2021:S1542-3565(21)00968-X. [PMID: 34508869 DOI: 10.1016/j.cgh.2021.09.004] [Reference Citation Analysis]
11 Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Lampertico P, Berg T. Reply to: Correspondence on 'the times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy.'. J Hepatol 2021:S0168-8278(21)02009-2. [PMID: 34454996 DOI: 10.1016/j.jhep.2021.08.014] [Reference Citation Analysis]
13 Enomoto M, Umemura T, Suzuki F. I shall be released (from infinite HBV nucleos(t)ide analog therapy): Japanese experience. J Hepatol 2021:S0168-8278(21)01894-8. [PMID: 34245805 DOI: 10.1016/j.jhep.2021.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jeng WJ, Chien RN, Liaw YF. Disputing issues in the paradigm change to finite antiviral therapy in HBeAg negative patients. J Hepatol 2021:S0168-8278(21)01847-X. [PMID: 34214616 DOI: 10.1016/j.jhep.2021.06.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Papatheodoridi M, Papatheodoridis G. New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B. J Hepatol 2021:S0168-8278(21)00440-2. [PMID: 34171438 DOI: 10.1016/j.jhep.2021.06.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Mak LY, Seto WK, Yuen MF. Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses 2021;13:1169. [PMID: 34207458 DOI: 10.3390/v13061169] [Cited by in F6Publishing: 5] [Reference Citation Analysis]